• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention relates to a process for the preparation of nilotinib intermediate, 3- (4-methyl-1H-imidazol-1-yl) -5-trifluoromethylphenylamine (I), comprising the following steps: benzotrifluoride is used as starting material, and the nilotinib- Intermediate (I) is obtained by nitration, bromination, condensation and reduction. Compared to the prior art, this production process has higher yield, readily available raw materials, simple processes and few side reactions. It is suitable for industrial production and will promote the development of the economical technique of the drug.
    公开号:CH710806B1
    申请号:CH00864/16
    申请日:2014-12-25
    公开日:2018-03-29
    发明作者:Xuenong Xu；Zhijian Bao；Jia Xue；Liang Shu；Lingling Xie；Dongliang Huang；Wei Chen；Deli Zeng；Qing Zhang；Jian Su
    申请人:Suzhou lixin pharmaceutical co ltd；Xuenong Xu；
    IPC主号:
    专利说明:

    TECHNICAL FIELD The invention relates to a technical field of development of the organic synthesis pathways and production of drugs and their intermediates, and more particularly relates to a process for the production of Niloti nib intermediate.
    Prior Art Nilotinib (the chemical name: 4-methyl-3- [4- (3-pyridinyl) -2-pyrimidinyl] amino-N- [5- (4-methyl-1H-imidazole-1 - yl) -3- (trifluoromethyl) phenyl] benzamide) is an oral highly selective tyrosine kinase inhibitor developed by Switzerland Novartis AG. Its monohydrochloride monohydrate was approved by the FDA in Oct. 2007 and launched on the market under the brand name Tasigna. It is used to treat chronic myeloid leukemia, which Ima-tinib has no effect on. This drug can selectively inhibit tyrosine kinase and the Philadelphia chromosome-positive chronic myeloid leukemia caused by its mutation from the coding genes by targeting. It has good tolerability for the patients, good selectivity and significant effect.
    There are already many reports on the process for producing nilotinib. Most affected are two important intermediates, namely 3- (4-methyl-1 H -imidazol-1-yl) -5-trifluoromethylaniline (I) and 4-methyl-3 - [[4- (3-pyridinyl ) -2-pyrimidinyl] amino] benzoic acid (II)
    The preparation of the intermediate (I) is carried out mainly by the following synthetic routes.
    Patent WO 2004/00 528 and WO 2006/135 640 report that the intermediate (I) from 3-fluoro-5-trifluoromethylbenzonitrile and 4-methyl-1H-imidazole as starting materials by nucleophilic substitution, hydrolysis -, Curtius rearrangement and hydrolysis reaction is obtained.
    The patents WO 2006/135 640 and WO 2006/135 641 report a different synthesis method, wherein the intermediate product (I) of 1-bromo-3-fluoro-trifluoromethylbenzene and 4-methyl-1H-imidazole as starting materials by two-stage nucleophilic Substitution reaction and hydrolysis reaction is obtained.
    The above patents still report that the target intermediate (I) is obtained from l-bromo-4-fluoro-2-trifluoromethyl-benzene as the starting material by nitration, reduction, nucleophile substitution reaction.
    The patents WO 2006/022 026, WO 2008/038 042 and "Chinese Journal of Pharmaceuticals" 2013, Voi. 44, No. 1, p. 17, report another method wherein the target intermediate (I) is obtained from benzotrifluoride as the starting material through the reactions of double-nitration, substitution and reduction.
    The patents WO 2009/049 028, WO 2010/009 402 and "Synthesis" 2007, Voi. 14, p. 2121, report a common method wherein the target intermediate (I) is obtained from benzotrifluoride as the starting material through the reactions of mono-nitration, bromination, reduction and condensation substitution.
    In the existing processes for the preparation of nilotinib intermediate (I) there are usually many problems, e.g. In comparison, it is the usual method that 3-bromo-5-nitro-benzofluoride is first reduced to 3-bromo-5-nitro-trifluoromethylaniline and the target product is obtained by condensation becomes. The reason is that the condensation reaction, the mechanism of which is nucleophilic substitution, is more easily carried out when the nitro group is reduced to amino and the benzene ring is activated. According to literature reports, the yield can reach more than 70%. During the investigation, the inventors have found that practically by different selection of temperature, type and amount of the catalyst and the acid binder the own bromine and amino group of raw materials are condensed so to speak coupled. The coupling product is more than 50%, so that the result is influenced on an industrial scale.
    In order to thoroughly solve the problems of self-coupling of 3-bromo-5-trifluoromethylaniline, it is the best choice if the condensation reaction prior to the reduction of 3-bromo-5-nitrobenzotrifluoride is carried out, first, 3- (4-me -thyl-1H-imidazol-1-yl) -5-nitro-benzotrifluoride, then reducing the nitro group to the target nilotinib intermediate (I). In the new development idea, the coupling side reaction is prevented because the nitro group is not condensed and coupled with the bromo group itself. However, the activity of the target condensation reaction due to the inactivation of the nitro group is significantly reduced. Patent WO 2006/135 640 reports this synthetic route, wherein 3-bromo-5-nitro-benzotriFluorid and 4-methyl-1H-imidazole is condensed with the aid of catalyst and base and the yield is only 20-30%, which is the industrial Production is not applicable.
    It is necessary to find a new process for the preparation of nilotinib intermediate, 3- (4-methyl-1H-imidazol-yl) -5-trifluoromethylaniline (I), wherein the raw materials are readily available easy to operate, and side reactions and environmental impact are reduced.
    Summary of the Invention It is the object of the present invention to provide an improved process for preparing the nilotinib intermediate, 3- (4-methyl-1H-imidazol-1-yl) -5-trifluoromethylaniline (I), wherein by selecting and optimizing cocatalyst, mixed acid binding agent and suitable temperature for the condensation reaction and several reduction methods, the yield of the target product is significantly increased, the raw materials are more readily available, and the side reactions can be reduced, which is suitable for industrial production.
    To solve the problem, the following technical solution is used in the present invention: a process for the preparation of nilotinib intermediate, 3- (4-methyl-1H-imidazol-1-yl) -5-trifluoromethylphenylamine ( I), characterized in that the manufacturing method comprises the following steps:
    m-Nitrobenzotrifluoride is obtained from benzotrifluoride as the starting material by nitration, 3-bromo-5-nitrobenzotrifluoride is obtained by bromination of m-nitrobenzotrifluoride, 3- (4-methyl-1H-imidazol-1-yl) -5-nitrobenzotrifluoride is using of catalyst, cocatalyst and mixed acid-binding agent by condensation reaction of 3-bromo-5-nitrobenzotrifluoride and 4-methyl-1H-imidazole, and the nilotinib intermediate (I) is obtained by the reduction reaction of 3- (4-methyl-1H-imidazole -1-yl) -5-nitrobenzotrifluoride.
    The invention further comprises the following dependent technical solutions: The catalyst for the condensation reaction is Cui, Znl, Snl, PdCl 2 or Agl, preferably Cui.
    The cocatalyst for the condensation reaction is 8-hydroxyquinoline, 2,6-lutidine, 4-dimethylaminopyridine, N-methylmorpholine, N-ethylmorpholine, 1,5-diazabicyclo [4.3.0] -non-5-ene, l, 8-diazabicyclo [5.4.0] undec-7-ene or 1,4-diazabicyclo [2.2.2] octane, preferably 8-quinolinol or 1,8-diazabicyclo [5.4.0] undec-7-ene.
    The mixed acid-binding agent for the condensation reaction consists of any of NaH, KH, NaOH, KOH, Na 2 CO 3, K 2 CO 3, sodium tert-butoxide, potassium tert-butoxide, sodium methoxide or sodium ethoxide and any of triethylamine, ethylenediamine or diisopropylethylamine , preferably from K 2 CO 3 and triethylamine or from potassium tert-butoxide and ethylenediamine.
    The solvent for the condensation reaction is xylene, dioxane, dimethyl sulfoxide, Ν, Ν-dimethylformamide or Ν, Ν-Diemthylacetamid, preferably dimethyl sulfoxide or N, N-dimethylformamide.
    The temperature for the condensation reaction is 120-160 ° C, preferably 130-150 ° C.
    The reducing agent for the reduction reaction is Fe, Zn, Sn, Na 2 S 2 O 2, hydrazine hydrate or hydrogen, preferably hydrazine hydrate or hydrogen.
    In the case of hydrogen as a reducing agent, the catalyst for the hydrogenation reaction is palladium on carbon, Raney nickel, Pd (OH) 2 on carbon or platinum on carbon, preferably palladium on carbon.
    Compared to the prior art, the present invention has the following advantages that by selecting and optimizing the catalyst, cocatalyst, mixed acid binding agent and suitable temperature for the condensation reaction, the activity of the condensation reaction is increased, the inactivating effect of the nitro group on Aryl group is overcome and the conversion rate is increased, whereby the efficiency of the atoms, the selectivity of the reaction and the controllability of the operation are improved, so that the production of nilotinib intermediate (I) is more controllable, the costs are significantly reduced and the development of economic Technology is promoted by the drug.
    EMBODIMENT The technical solution of the present invention will be explained in more detail with reference to the following preferred embodiments.
    Embodiment 1: 15 ml of 60-65% concentrated HNO 3 and 30 ml of 98% concentrated H 2 SO 4 are mixed at a low temperature of 0 to 10 ° C. Benzotrifluoride (29.2 g, 0.2 mol) is added dropwise at 0-5 ° C. Thereafter, the reaction is carried out at room temperature for 8 hours and monitored by TLC until the starting material is completely reacted. The batch is poured into ice-water, extracted with ethyl acetate, washed with 10% NaOH, dried and treated under reduced pressure to remove the solvents. This gives 34.0 g of light yellow clear liquid m-nitrobenzotrifluoride with a yield of 89.0% and a boiling point of 105-107 ° C (4kPa) which can be used in the next reaction without further purification.
    权利要求:
    Claims (5)
    [1]
    1. A process for the preparation of the nilotinib intermediate, 3- (4-methyl-1H-imidazol-1-yl) -5-trifluoromethyl-1H-Ipheny-la-min (I),

    characterized in that the process comprises the following steps: m-nitrobenzotrifluoride is obtained by nitration of benzotrifluoride as starting material, 3-bromo-5-nitro-benzotrifluoride is obtained by bromination of m-Ni-trobenzotrifluoride, 3- (4-methyl- 1 H -imidazol-1-yl) -5-nitro-benzotrifluoride is obtained by condensation of 3-bromo-5-nitro-benzotrifluoride and 4-methyl-imidazole with the aid of catalyst, cocatalyst and mixed acid-binding agent, and the nilotinib intermediate (I) is obtained by reduction of 3- (4-methyl-1H-imidazol-1-yl) -5-nitro-benzotrifluoride, wherein the catalyst for the condensation reaction Cul, Znl, PdCl 2 or Agl, the cocatalyst for the Condensation reaction 8-hydroxyquinoline, 2,6-lutidine,
    [2]
    2. A process for the preparation of the nilotinib intermediate according to claim 1, characterized in that the solvent for the condensation reaction xylene, dioxane, dimethyl sulfoxide, Ν, Ν-dimethylformamide or N, N-dimethylacetamide.
    [3]
    3. A process for the preparation of nilotinib intermediate according to claim 1, characterized in that the temperature of the condensation reaction between 120 ° C and 160 ° C.
    [4]
    4. A process for the preparation of nilotinib intermediate according to claim 1, characterized in that the reducing agent for the reduction reaction is iron, zinc, tin, sodium dithionite, hydrazine hydrate or hydrogen.
    4-dimethylaminopyridine, N-methylmorpholine, N-ethylmorpholine, 1,5-diazabicyclo [4.3.0] - non-5-ene, 1,8-diazabicyclo [5.4.0] undec-7-ene or 1, 4-diazabicyclo [2.2.2] octane, and the mixed acid-binding agent for the condensation reaction is any of NaH, KH, NaOH, KOH, Na 2 CO 3, K 2 CO 3, sodium tert-butoxide, potassium tert-butoxide, sodium methylate or sodium ethoxide and any of triethylamine, ethylenediamine or diisopropylethylamine.
    [5]
    5. A process for the preparation of nilotinib intermediate according to claim 4, characterized in that the catalyst used for the hydrogenation reaction is palladium on carbon, Raney nickel, Pd (OH) 2 on carbon or platinum on carbon, when hydrogen as the reducing agent is used.
    类似技术:
    公开号 | 公开日 | 专利标题
    EP0027555B1|1984-01-04|Process for the preparation of diphenyl ethers
    EP2285779A1|2011-02-23|Method for manufacturing aryl carboxamides
    CH710806B1|2018-03-29|Process for the preparation of nilotinib intermediate.
    CN110028489B|2021-08-06|Method for preparing benzamide compound by pressure reduction method
    EP0365915B1|1994-04-20|Substituted 2-aminothiazoles
    DE1620016B2|1979-01-04|3- | pyrazoles and processes for their preparation
    CH629776A5|1982-05-14|METHOD FOR PRODUCING NEW PHENYLAZACYCLOAL CHANES.
    DE102010046720A1|2012-03-29|Process for the preparation of pan-CDK inhibitors of the formula |, as well as intermediates of the preparation
    DE4432610C1|1996-02-01|Process for the preparation of selegiline hydrochloride
    DE2654852C3|1979-05-31|Process for the preparation of aromatic amines from α, ß-unsaturated cycloaliphatic ketoximes
    EP0923534B1|2000-10-04|Process for preparing racemic phenethylamines
    CN103880751A|2014-06-25|Preparation method of imidafenacin
    EP0086450B1|1986-05-28|Substituted phenylpyrazole derivatives, process for their preparation, medicines based on these compounds and their use
    DE4239000A1|1994-05-26|Multistage prepn. of Toltrazuril without isolating intermediates - starting from 4-tri:fluoromethyl- mercapto-phenol, 2-chloro-5- nitrotoluene, phosgene and N-methyl urea
    DE3816634A1|1988-11-24|CYCLOBUTEN-3,4-DION INTERMEDIATE COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
    EP2179988A1|2010-04-28|Producing | aryl ethers
    CN108203384B|2021-03-16|Method for preparing o-nitrobenzyl bromide
    DE3924365A1|1991-01-24|2-AMINO-7-CARBAMOYL-1,2,3,4-TETRAHYDRONAPHTHALINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICAMENT
    DE3815046A1|1989-11-16|3-CHLORINE-2-METHYLPHENETHYLAMINE DERIVATIVES
    DE60308170T2|2007-01-04|PROCESS FOR THE PREPARATION OF CHINOLINE DERIVATIVES
    EP0088346B1|1985-06-05|2-aminomethyl-phenol derivatives, process for their preparation, their use and pharmaceutical compositions containing them
    AT213864B|1961-03-10|Process for the preparation of new analgesic α-amino-β-oxybutyric acid amides
    DE1793611B2|1973-06-07|4,4-DIPHENYLCYCLOHEXYLAMINE, THEIR ACID-ADDITIONAL SALTS AND QUARTER AMMONIUM SALTS
    AT281856B|1970-06-10|Process for the preparation of new N1-benzenesulfonyl-N2- | -ureas
    AT164533B|1949-11-25|Process for the production of new ethylenediamine derivatives
    同族专利:
    公开号 | 公开日
    CN103694176A|2014-04-02|
    WO2015103927A1|2015-07-16|
    CN103694176B|2015-02-18|
    US20160311777A1|2016-10-27|
    US10392351B2|2019-08-27|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    GB0214459D0|2002-06-21|2002-07-31|K Pow Ltd|Moulded-plastics articles|
    CA2578060A1|2004-08-26|2006-03-02|Test Research Laboratories Inc.|Semiconductor test system|
    SA2351B1|2005-06-09|2009-12-22|نوفارتيس ايه جي|Process for the Synthesis Of 5--3--benzenamine|
    MY146795A|2005-06-09|2012-09-28|Novartis Ag|Process for the synthesis of organic compounds|
    GB0618832D0|2006-09-25|2006-11-01|Phoenix Chemicals Ltd|Chemical process|
    WO2009049028A1|2007-10-09|2009-04-16|Targegen Inc.|Pyrrolopyrimidine compounds and their use as janus kinase modulators|
    WO2010009402A2|2008-07-17|2010-01-21|Teva Pharmaceutical Industries Ltd.|Nilotinib intermediates and preparation thereof|
    CN103694176B|2014-01-07|2015-02-18|苏州立新制药有限公司|Preparation method of nilotinib intermediate|CN103694176B|2014-01-07|2015-02-18|苏州立新制药有限公司|Preparation method of nilotinib intermediate|
    EP3095782A1|2015-05-18|2016-11-23|Esteve Química, S.A.|New method for preparing 3--5-benzenamine|
    TW202116321A|2018-06-15|2021-05-01|美商漢達生技醫藥責任有限公司|Use of nilotinib lauryl sulfate salt dosage form for treating chronic myeloid leukemia|
    法律状态:
    2017-02-28| PK| Correction|Free format text: BERICHTIGUNG ERFINDER |
    2020-06-15| PCAR| Change of the address of the representative|Free format text: NEW ADDRESS: BADSTRASSE 5 POSTFACH, 8501 FRAUENFELD (CH) |
    2020-10-15| PCAR| Change of the address of the representative|Free format text: NEW ADDRESS: BAHNHOFSTRASSE 100, 8001 ZUERICH (CH) |
    优先权:
    申请号 | 申请日 | 专利标题
    CN201410005290.9A|CN103694176B|2014-01-07|2014-01-07|Preparation method of nilotinib intermediate|
    PCT/CN2014/094891|WO2015103927A1|2014-01-07|2014-12-25|Method for preparing nilotinib intermediate|
    [返回顶部]